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Vitamin K antagonists have been recommended as the only available oral anticoagulants for
stroke prevention in patients with atrial ﬁbrillation for many years. Despite their proved
effectiveness, there are several limitations and drawbacks of this therapy. Recently three major
clinical trials of novel oral anticoagulants clinical trials have been published. Dabigatran, a direct
thrombin inhibitor, as well as rivaroxaban and apixaban, direct Xa factor inhibitors, were found to
have at least noninferior efﬁcacy and safety in comparison to vitamin K antagonists for stroke
prevention in patients with non-valvular ﬁbrillation. These novel oral anticoagulants may
constitute a valuable alternative to vitamin K antagonists.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All rights
reserved.
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Atrial ﬁbrillation (AF) is the most common arrhythmia in clinical
practice. AF increases almost ﬁve-fold the independent risk of
ischemic stroke [1]. AF related strokes account for at least 20% of
all strokes and are associated with worse survival [2]. For morech Society of Cardiology. Pu
9 30.
yzdol@op.pl (M. Syzdół).than 60 yr, vitamin K antagonists (VKAs) have been the reference
standard treatment of AF with risk factors for stroke. Until
recently VKAs were the only available oral anticoagulants for
stroke and systemic embolism prevention in patients with AF [3].
Warfarin, the most commonly used VKA, reduces stroke risk by
64% compared with 22% reduction with any antiplateletblished by Elsevier Urban & Partner Sp.z o.o. All rights reserved..
Table 1 – Main characteristics of novel oral anticoagulants.
DABIGATRAN RIVAROXABAN APIXABAN
Point of action IIa Xa Xa
tmax (h) 0.5–2 2–4 1–4
t1/2 (h) 12–17 5–13 8–15
Bioavailability (%) 6.5% 60–80% 50%
Active drug clearance 80% renal; 20% liver 33% renal; 66% liver 25% renal; 75% liver
CYP 450 no 3A4/2J2 3A4
Prodrug Dabigatran etexilate no no
Dose 110 mg or 150 mg b.i.d. 20 mg o.d. 5 mg b.i.d.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 9 5 – e 1 0 0e96treatment, and 19% risk reduction with aspirin alone in nonvalv-
ular AF [4]. Despite VKAs effectiveness, there are several limita-
tions and drawbacks of this anticoagulation therapy. The
international normalized ratio (INR) therapeutic index 2.0–3.0 is
the optimal value for stroke prevention. Below this narrow range
stroke and systemic embolism prevention is ineffective, but
higher values signiﬁcantly increase the risk of hemorrhage [5].
Major bleeding occurs in about 2% of patients with AF on VKAs
treatment per year [6]. Signiﬁcantly increased risk of hemorrhage
is the result of the long VKAs half-life, delayed action onset, high
inertion after withdrawal and necessity of heparin bridging
therapy during urgent surgical procedures. As it is known from
clinical trials, patient presenting with AF are in the therapeutic
INR range only during 60% of treatment time and data from
everyday practice show that this time is even shorter [7,8].
Numerous food and drug interactions, wide variations in meta-
bolism and individual response to drug doses explain the require-
ment for frequent laboratory monitoring and adequate VKAs
dosage. To achieve therapeutic INR range appropriate patient
education and strict compliance is necessary.
In the last decade, several novel oral anticoagulants (NOACs)
were developed, but so far only three major randomized phase III
clinical trials have been completed and published. Dabigatran, the
oral direct thrombin inhibitor, as well as two oral factor Xa inhibitors
—rivaroxaban and apixaban, were found to have at least noninferior
efﬁcacy and safety in comparison to VKAs. No need for routine
laboratory monitoring because of predictable anticoagulant effect,
ﬁxed dosage, as well as very few drug- and no food interactions are
the major advantages of NOACs. The summary of the main
pharmacokinetic properties of NOACs is presented in Table 1.2. Dabigatran
Administered orally as a prodrug, dabigatran etexilate is a direct
inhibitor of thrombin that converts ﬁbrinogen into ﬁbrin and
promotes thrombus formation. Dabigatran inactivates free and
clot-bound thrombin, which prevents thrombus expansion. After
intestinal acid sensitive absorption, blood esterases convert dabiga-
tran etexilate into the active metabolite. To promote the process of
absorption, dabigatran tablets contain a tartaric acid core which
could be responsible for higher rates of dyspepsia. Proton pump
inhibitors reduce dabigatran bioavailability by about 20%, but with-
out clinical signiﬁcance and necessity of dosage adjustment. Dabi-
gatran is not metabolized by the P450 cytochrome, so only very few
drugs (verapamil, amiodarone, quinidine, macrolides, tenophovir,
rifampicin and St John's wort) can interact with it. The bioavailability
and metabolism is also not inﬂuenced by food. The maximumplasma concentration is reached within 0.5–2 h, and the half-life
time is 12–17 h. In case of emergency (overdosage, urgent surgical
procedure) dabigatran can be dialyzed because of its low plasma
protein binding. It is eliminated unchanged mostly via renal excre-
tion, and only 20% is excreted to bile, thus in patients with renal
insufﬁciency dose adjustment and regular creatinine clearance
monitoring is necessary [9–11].
RE-LY was a randomized, phase III trial comparing two doses
of dabigatran etexilate (110 mg b.i.d. and 150 mg b.i.d.) with
open-label, dose-adjusted warfarin to an INR of 2.0–3.0. The
150 mg b.i.d. of dabigatran dose was superior to warfarin for the
primary efﬁcacy end-point of stroke and systemic embolism, with
no signiﬁcant differences in the risk of major bleeding. Dabigatran
at a dose of 110 mg was safer than warfarin with 20% less major
bleeding and non-inferior to warfarin in the prevention of stroke
and systemic embolism. There was a non-signiﬁcant reduction in
all-cause mortality, while the rates of hemorrhagic stroke and
intracranial hemorrhage were lower with both doses of dabiga-
tran [12,13]. A signiﬁcant age interaction was also reported, with
the beneﬁcial effect better expressed in patients younger than
75 yr [14]. Beneﬁts of dabigatran treatment over the VKA were
independent of quality of INR control [15], prior stroke [16] or
prior VKA usage [17]. In patients with AF who undergo cardiover-
sion the rates of stroke and major bleeding within 30 days of
cardioversion, on both doses of dabigatran were comparable to
those on warfarin [18].3. Rivaroxaban
Rivaroxaban is an oral direct inhibitor of factor Xa which is
playing a critical role at the intersection of intrinsic and extrinsic
pathways of the coagulation cascade and thrombin generation.
Rivaroxaban, without the need of a cofactor, can inhibit not only
free factor Xa but also the prothrombinase- and clot-bound factor
Xa. Rivaroxaban has a good bioavailability and its absorption is
increased by food, so it is recommended to take the drug with or
shortly after meals. After absorption, rivaroxaban is metabolized
by CYP 3A4 or 2J2, therefore there are several interactions with
drugs like antimycotic azole or HIV protease inhibitors, with
signiﬁcant increases in plasma concentrations. The maximum
blood level is reached within 2–4 h, and the half-life time is
5–13 h. Unlike dabigatran, rivaroxaban is insoluble in water and
has high plasma protein binding, so may not be dialyzable. It is
eliminated mostly via renal excretion (one third in the active,
unchanged form and two thirds in the form of liver metabolites),
and only about 25% with faces. Therefore, rivaroxaban is contra-
indicated in patients with severe hepatic or renal failure [19,20].
HR and 95% CI
RE LY DABIGATRAN 110 mg ITT HR 0 90; 95% CI 0 74 1 10; P=0 29- -  - . , . - . .
RE-LY - DABIGATRAN 150 mg - ITT  HR 0.65; 95% CI, 0.52-0.81; P<0.001
ROCKET - RIVAROXABAN - ITT  HR 0.88; 95% CI, 0.75-1.03; P=0.12
ROCKET RIVAROXABAN Safety as treated HR 0 79; 95% CI 0 65 0 95; P=0 02
ARISTOTLE - APIXABAN - ITT  HR 0.79; 95% CI, 0.66-0.95; P=0.01
 -  - , . , . - . .
0.2 0.5 1 2 5
Favors study drug Favors warfarin
Fig. 1 – Primary efficacy end-point—NOACs trials (HR—hazard ratio; CI—confidence interval; ITT—intention to treat; p—level
of significance for superiority). Adapted from [28].
Table 2 – Comparison of NOACs trials. Adapted from [28].
RE-LY [12] ROCKET AF [21] ARISTOTLE [25]
Study drug Dabigatran Rivaroxaban Apixaban
Comparator warfarin (I N R 2–3)
N 18,113 14,264 18,201
Study design Open-label (warfarin) non-
inferiority
Double-blind non-inferiority Double-blind non-inferiority
Dose 110 mg b.i.d. or 150 mg b.i.d.
(randomized to 2 separate arms)
20 mg o.d. 15 mg o.d. for moderate renal
impairment (CrCl 30–49 ml/min)
5 mg b.i.d. 2.5 mg b.i.d. for
patients with ≥2 at baseline:
age ≥80 years; weight
≤60 kg; serum creatinine
≥1.5 mg/dl
Primary efﬁcacy
end-point
Stroke and systemic embolism
Primary safety
end-point
Major bleeding Composite of major and non-major clinically
relevant bleeding
Major bleeding
Inclusion
criteria
Patients with ≥1: Patients with prior stroke, TIA or SE or ≥2: Patients with ≥1:
• prior stroke, TIA or SE
• CHF or LVEF≤40%
• age≥75
• age≥65 and 1 of: -DM-HT-CAD
• CHF or LVEF≤35%
• HT
• age≥75
• DM
• prior stroke, TIA or SE
• CHF or LVEF ≤40%
• age≥75
• DM
• HT
Major bleeding Bleeding associated with: Clinically overt bleeding associated with: Clinically overt bleeding
associated with:
• ↓ Hb ≥2 g/dl
• transfusion of ≥2 U of blood
• symptomatic bleeding in a
critical area or organ
• ↓ Hb ≥2 g/dl
• transfusion of ≥2 U of RBC/whole blood
• fatal bleeding
• critical anatomic site bleeding
• permanent disability
• ↓ Hb ≥2 g/dl
• transfusion of ≥2 U of RBC
• fatal bleeding
• critical site bleeding
Mean CHADS2 2.1 3.5 2.1
NOACs—novel oral anticoagulants; TIA—transient ischemic attack; SE—systemic embolism; CHF—chronic heart failure; LVEF—left ventricle ejection
fraction; DM—diabetes mellitus; HT—hypertension; CAD—coronary artery disease.
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c o r e t v a s a 5 5 ( 2 0 1 3 ) e 9 5 – e 1 0 0e98Patients with non-valvular AF were randomized in the ROCKET
AF phase III trial in double-blind, double-dummy fashion to either
active treatment (20 mg o.d. or 15 mg o.d. in patients with
creatinine clearance 30–49 ml/min) or dose-adjusted warfarin.
Rivaroxaban was non-inferior to warfarin in preventing stroke or
systemic embolism in the intention-to-treat population and even
superior in the safety as-treated population analysis. There
were no differences in the composite primary safety end-point
composed of major and non-major clinically relevant bleeding.
Rivaroxaban signiﬁcantly reduced intracranial hemorrhages
and hemorrhagic strokes, while transfusions and major gastro-
intestinal bleedings occurred more frequently [21]. The efﬁcacy
and safety of rivaroxaban was similar in the subgroups of patients
with and without previous stroke or TIA. This subgroup analysis
showed that rivaroxaban provides effective anticoagulation in
primary as well as in secondary stroke prevention [22].4. Apixaban
Apixaban is another NOAC recommended in patients with non-
valvular AF. It is a direct, reversible, oral factor Xa inhibitor with
absorption independent from food administration. Apixaban
inhibits both free and prothrombinase- and clot-bound factor
Xa. About one third of the drug is metabolized by hepaticTable 3 – Recommendations for prevention of thromboemboli
Antithrombotic therapy is recommended for patients with AF besides th
contraindications.
According to the absolute risk of thromboembolism or bleeding and the
therapy should be chosen.
In patients with non-valvular AF with a CHA2DS2VASc score≥2 oral anti
dose-adjusted VKAs to a target INR of 2.0 to 3.0 or dabigatran, rivaroxaba
In patients with a CHA2DS2VASc score of 1 oral anticoagulation therapy
dabigatran, rivaroxaban, apixaban should be considered if there are no
In patients who are at low risk, with none of the risk factors (CHA2DS2V
recommended.
In female patients who are at low risk (ageo65 years with lone AF and
gender) no antithrombotic therapy should be considered.
In patients with AF where oral anticoagulation is required one of the NO
effects of VKAs likewise difficulties in keeping therapeutic range or regu
For most patients with non-valvular AF one of the NOACs should be con
Dabigatran at 150 mg b.i.d. should be preferred in most patients to 110 m
elderly patients (age480 yr), high bleeding risk (HAS-BLED score≥3), mo
49 ml/min) and interacting drugs treatment.
Rivaroxaban at 20 mg o.d. should be preferred in most patients to 15 mg
bleeding risk (HAS-BLED score≥3) and moderate renal failure (creatinine
In patients treated with one of the NOACs baseline and than regular rena
should be done annually and in patients with moderate renal impairme
In patients with severe renal failure (creatinine clearanceo30 ml/min) d
recommended.
VKA therapy or dabigatran is recommended for patients with AF of 48 h
unknown for at least 3 weeks prior to and for at least 4 week after card
Dose-adjusted VKAs or dabigatran, rivaroxaban, apixaban should be con
following cardioversion in patients with stroke risk factors or recurrentcytochrome CYP 3A4 and apixaban is eliminated mostly via bile
excretion, thus in patients presenting with renal failure is the
safest of all NOACs [23,24].
ARISTOTLE was a randomized, double-blind, double-dummy,
phase III trial of stroke or systemic embolism prevention compar-
ing apixaban at dose 5 mg b.i.d. (2.5 mg b.i.d. in patients ≥80 yr,
weight ≤60 kg or serum creatinine ≥1.5 mg/dl) and dose-adjusted
warfarin to an INR of 2.0–3.0. In the intention-to-treat population
analysis apixaban was superior to warfarin in the primary efﬁcacy
end-point (stroke or systemic embolism). Apixaban signiﬁcantly
reduced intracranial hemorrhage, major and non-major clinically
relevant bleeding and any bleeding, but most importantly also
reduced all-cause mortality [25]. Secondary analysis of the
ARISTOTLE trial shows that there was no difference in reduction
of stroke or systemic embolism across all score categories
(CHADS2, CHA2DS2VASc, HAS-BLED). Also the rates of major
bleeding were similar regardless of stroke or bleeding risk [26].
Reduction in rates of stroke or death compared to warfarin was
irrespective of renal function. Beneﬁts of apixaban treatment in
patients presenting with renal failure (creatinine clearance
≤50 ml/min) are due to a greater relative risk reduction in major
bleeding (HR 0.50; 95% CI 0.38–0.66; p¼0.005) [27].
The main goal in RE-LY, ROCKET AF and ARISTOTLE trials was
to demonstrate non-inferiority to VKAs for the primary efﬁcacy
and safety end-point in patients with non-valvular AF. Thesesm in non-valvular AF adapted from [29].
ose who are at low risk or with Class I. Level A.
benefit for a given patient the adequate Class I. Level A.
coagulation therapy is recommended with
n, apixaban if there are no contraindications.
Class I. Level A.
with dose-adjusted VKAs (2.0 to 3.0) or
contraindications.
Class IIa. Level A.
ASc score of 0) no antithrombotic therapy is Class I. Level B.
CHA2DS2VASc score of 1 because of their Class IIa. Level B.
ACs is recommended when there are side
lar monitoring of INR.
Class I. Level B.
sidered rather than dose-adjusted VKAs. Class IIa. Level A.
g b.i.d., but 110 mg b.i.d. is recommended in
derate renal failure (creatinine clearance 30–
Class IIa. Level B.
o.d., but 15 mg o.d. is recommended in high
clearance 30–49 ml/min).
Class IIa. Level C.
l function (creatinine clearance ) assessment
nt 2 to 3 times per year.
Class IIa. Level B.
abigatran, rivaroxaban and apixaban are not Class III. Level A.
duration or when the duration of AF is
ioversion.
Class I. Level B.
tinued lifelong regardless of sinus rhythm
AF.
Class I. Level B.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 9 5 – e 1 0 0 e99three trials proved the efﬁcacy of the novel anticoagulants at the
same level as VKAs. Apixaban, dabigatran at 150 mg b.i.d., and
rivaroxaban (in safety as treated analysis), were even superior to
VKAs in stroke or systemic embolism prevention [Fig. 1].
All of the NOACs conﬁrmed non-inferiority to VKAs in primary
safety end-point. Apixaban and dabigatran at 110 mg b.i.d. sig-
niﬁcantly reduced the rates of major bleeding and, what is
noteworthy; every tested NOAC decreased the number of intra-
cranial hemorrhages and hemorrhagic strokes. There are several
differences in trials design and outcomes. Trials comparison is
presented in Table 2.
Due to such favorable results of the NOACs phase III clinical
trials, the European Society of Cardiology updated the ESC guide-
lines for the management of AF for stroke or systemic embolism
prevention. Recommendations for prevention of thromboembo-
lism in non-valvular AF are presented in Table 3 [29].
Although data from NOACs trials are encouraging, there are
several practical aspects that still should be elucidated. Safety of
long-term treatment and all drug or food interactions are not
completely known. Relatively short half-life requires strict patient
compliance to assure appropriate anticoagulation levels. Missing
more than one dose may result in loosing anticoagulant protec-
tion. No need of laboratory monitoring is the advantage of NOACs,
but in some urgent cases it could be also a disadvantage. Several
immediate surgical procedures require certainty of correct coa-
gulation status, which cannot be precisely measured in currently
available laboratory tests. Prior to elective procedures NOAC
treatment should be interrupted. The time of dabigatran cessation
depends on creatinine clearance. In patients with creatinine
clearance more than 80 ml/min treatment should be stopped for
24 h, respectively 50–80 ml/min for 1–2 days and 30–50 ml/min
for 2–3 days before a surgical procedure, coronary angiography or
cardiac pacemaker implantation. In patients treated with rivar-
oxaban at least 24 h interval is obligatory before any invasive
procedures [30]. Moreover, the lack of speciﬁc antidote that can
be used prior to urgent procedures or in case of overdosage is also
a disadvantage and needs additional exploration. There are some
data from healthy volunteers showing the effectiveness of pro-
thrombin complex concentrate or low-dose FEIBA (factor eight
inhibitor bypassing agent) in anticoagulation effect of rivaroxaban
or dabigatran reversal [31,32]. There are preliminary data showing
the cost-effectiveness of NOAC treatment in every-day clinical
practice, but this needs further precise investigation.
Dabigatran, rivaroxaban and apixaban constitute a valuable
alternative to VKAs in patients with non-valvular AF, ﬁrmly
establish their role in the anticoagulation therapy.
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